Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2022; unaudited. Enanta is a biotechnology company whose principal revenue source is royalties from AbbVie’s HCV treatment MAVYRET/MAVIRET. It is developing wholly owned programs focused primarily on RSV, SARS-CoV-2, HBV and hMPV.
Financial results and liquidity
| Metric | Q1 FY2023 | Q1 FY2022 |
|---|---|---|
| Total revenue | $23.6 million | $27.6 million |
| Operating expenses | $53.6 million | $58.1 million |
| Operating loss | $30.0 million | $30.4 million |
| Net loss | $29.0 million | $30.1 million |
| Net loss per share | $1.39 | $1.48 |
| Cash used in operating activities | $35.6 million | $13.3 million |
- Royalty revenue was $22.6 million, down $5.1 million (about 18%) year over year. Enanta also recorded $1.0 million in upfront license revenue from an antibacterial compound it no longer develops.
- Research and development expense was $40.9 million, down from $48.5 million; G&A expense rose to $12.7 million from $9.5 million. The filing attributes lower R&D spending mainly to trial and manufacturing timing and the wind-down of its NASH program; higher G&A reflected stock compensation and headcount.
- Cash, cash equivalents and short- and long-term marketable securities totaled $241.4 million at December 31, 2022. The company had no debt outstanding. Total liabilities were $46.7 million and stockholders’ equity was $300.8 million.
- Operating cash use increased year over year, reflecting timing of R&D payments and an $8.5 million federal tax refund received in the prior-year quarter. Investing activities provided $33.6 million, principally reflecting net maturities and sales of marketable securities; financing activities provided $0.3 million.
Changes, outlook and risks
- Net loss narrowed modestly year over year, while revenue declined as AbbVie reported lower HCV sales and patient volumes remained below pre-pandemic levels. Royalty rates reset to their lowest tier each calendar year.
- Management expects continued losses for the foreseeable future and generally higher R&D spending as programs advance. It estimates existing financial resources plus continuing HCV royalties will fund operations into approximately the fourth quarter of fiscal 2024; actual runway may differ.
- Clinical outlook: EDP-323 Phase 1 data and EDP-235 Phase 2 data were expected in the second quarter of 2023. If supported by SPRINT results, Enanta expected to initiate an EDP-235 Phase 3 study in the second half of 2023. RSV studies were expected to continue through 2023, with enrollment and readout timing dependent in part on RSV epidemiology. The company also planned to select a dual hMPV/RSV candidate in the fourth quarter of 2023.
- Material uncertainties include dependence on AbbVie royalties, HCV market recovery and royalty tiers; clinical, regulatory and commercialization risks; possible need for additional financing; and potential trial delays or cost changes. Enanta is suing Pfizer for alleged infringement of a coronavirus-protease patent relating to Paxlovid and is seeking damages; the filing provides no outcome or quantified recovery. The company records legal expenses as incurred.
- The filing reported no material changes to the risk factors in the 2022 Form 10-K, no material changes in internal control over financial reporting, and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Subsequent MAVYRET/MAVIRET sales, HCV patient volumes and royalty revenue, including the annual royalty-tier reset.
- Actual operating cash burn and whether the stated runway into approximately Q4 FY2024 remains achievable as clinical spending changes.
- EDP-235 and RSV trial results, enrollment progress and timing relative to management’s stated expectations.
- Progress and potential costs or outcomes of the Pfizer patent litigation; no damages estimate is stated in the filing.
- Whether additional financing or partnering becomes necessary, and any resulting effect on shareholders.